Dbv Technologies S.a. - Spons-adr (DBVT)
$0.61
+0.01
(+1.16%)▲
Performance
- $0.54$0.63$0.61
11.44%
Downside
Day's Volatility :14.24%
Upside
3.16%
- $0.44$2.14$0.61
27.72%
Downside
52 Weeks Volatility :79.4%
Upside
71.5%
Returns
| Period | Dbv Technologies S.a. - Spons-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -29.62% | -5.7% | 0.0% |
6 Months | -48.44% | 3.0% | 0.0% |
1 Year | -61.35% | 13.4% | 0.0% |
3 Years | -90.02% | 11.4% | -21.2% |
Highlights
Market Capitalization | 58.3M |
Book Value | $0.56 |
Earnings Per Share (EPS) | -1.06 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.483 |
Profit Margin | 0.0% |
Operating Margin TTM | -2829.2% |
Return On Assets TTM | -46.25% |
Return On Equity TTM | -103.11% |
Revenue TTM | 12.5M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | -54.800000000000004% |
Gross Profit TTM | 4.8M |
EBITDA | -79.7M |
Diluted Eps TTM | -1.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.19 |
EPS Estimate Next Year | -1.01 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.31 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 798.77%
Technicals Summary
Sell
Neutral
Buy
Dbv Technologies S.a. - Spons-adr is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Dbv Technologies S.a. - Spons-adr | -22.6% | -48.44% | -61.35% | -90.02% | -96.07% |
 Regeneron Pharmaceuticals, Inc. | -18.71% | -22.43% | -5.78% | 15.35% | 104.57% |
 Biontech Se | 6.59% | 28.29% | 22.81% | -66.7% | 449.23% |
 Alnylam Pharmaceuticals, Inc. | -11.56% | 69.09% | 57.25% | 40.39% | 116.61% |
 Vertex Pharmaceuticals Incorporated | -2.48% | 3.96% | 33.86% | 144.36% | 109.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Dbv Technologies S.a. - Spons-adr | NA | NA | 0.0 | -1.19 | -1.03 | -0.46 | NA | 0.56 |
Regeneron Pharmaceuticals, Inc. | 18.25 | 18.25 | 1.1 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.06 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.22 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Dbv Technologies S.a. - Spons-adr | Buy | $58.3M | -96.07% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.1B | 104.57% | 18.25 | 33.61% |
Biontech Se | Buy | $28.4B | 449.23% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 116.61% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $120.3B | 109.5% | 32.84 | -4.51% |
Insights on Dbv Technologies S.a. - Spons-adr
Decreasing Revenue
Revenue is down for the last 3 quarters, 8.87M → 1.16M (in $), with an average decrease of 50.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -33.11M → -30.44M (in $), with an average increase of 8.8% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.3% return, outperforming this stock by 118.6%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.6% return, outperforming this stock by 124.4%
Institutional Holdings
Baker Bros Advisors LP
1.52%Yiheng Capital LLC
0.66%BRAIDWELL LP
0.34%Point72 Asset Management, L.P.
0.32%Vivo Capital, LLC
0.28%Morgan Stanley - Brokerage Accounts
0.13%
Company Information
dbv technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. dbv technologies (incorporated in 2002) has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. the viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. the product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. dbv technologies is focusing on food allergies (milk and
Organization | Dbv Technologies S.a. - Spons-adr |
Employees | 108 |
CEO | Mr. Daniel Tassé |
Industry | Health Technology |
